Through automated processing of diffusion-weighted magnetic resonance imaging (MRI) scans, the Advanced Neuro Diagnostic Imaging (ANDI) software performs detailed analysis of white matter microstructure.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Advanced Neuro Diagnostic Imaging (ANDI, Imeka), an artificial intelligence (AI)-enabled neuroimaging software that provides mapping of white matter microstructure on diffusion magnetic resonance imaging (MRI).
Employing a combination of modelling reconstruction algorithms, fiber bundling and tractography, the ANDI software platform assesses the microstructure of connecting white matter bundles through automated processing of diffusion-weighted MRI, according to Imeka.
The company said the ANDI software provides detailed analysis of the micro- and macrostructural values of white matter bundles and produces a subsequent DICOM-encapsulated PDF report noting white matter bundles that may have significant deviation from normative values.
“Imeka is pioneering AI in diffusion MRI-based white matter imaging to evaluate microstructural properties of white matter in greater detail than any other techniques,” noted Jean-Rene Belanger, the chief executive officer of Imeka.
Imeka added that recently announced CPT 3 codes from the American Medical Association (AMA) are geared toward quantitative brain MRI assessment and should facilitate reimbursement for use of the ANDI software.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.